In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer.
Is there a way to mend a broken heart? Biomedical engineers have found a potential way to mend a broken heart using a genetic mutation commonly associated with skin cancers.
Secarna Pharmaceuticals, the next-generation antisense drug discovery and development company, is developing novel approaches to successfully target Neuropilin 1 (NRP1), a promising target for the treatment of cancer.
Simon Holt, Honorary Professor at Swansea University, reflects on the key challenges within cancer care and the benefits of genomic testing in improving patient outcomes.
Consuming higher-quality ultra-processed foods (UPFs) might be linked to a higher risk of cancers in the upper aerodigestive tract, encompassing the mouth, throat, and oesophagus.
In a groundbreaking development, UCLA researchers from the Jonsson Comprehensive Cancer Center have unveiled an innovative artificial intelligence AI model. This model centred on epigenetic factors, demonstrates unparalleled success in predicting patient outcomes across cancer types.
Zisis Kozlakidis and Caboux Elodie from the International Agency for Research on Cancer discuss how the COVID-19 pandemic accelerated the adoption of changes in public health interventions and patient care.
Dr Avinash Hari Narayanan (MBChB), Clinical Lead at London Medical Laboratory, explores the key challenges in mesothelioma prevention, diagnosis and treatment.
